Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

Literature DB >> 25435371

Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

P Mapelli¹, E O Aboagye¹, J Stebbing¹, R Sharma².

Abstract

An understanding of epigenetic drivers of tumorigenesis has developed rapidly during the last years. The identification of these changes including DNA methylation and histone modifications in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a step forward in trying to define underlying biologic processes in this heterogeneous disease. The reversible nature of these changes represents a potential therapeutic target. We present an overview of the current knowledge of epigenetic alterations related to GEP-NETs, focusing on the influence and impact these changes have on pathogenesis and prognosis. The potential role of demethylating agents in the management of this patient population is discussed.

Entities: Disease Species

Mesh：

Substances：

Year: 2014 PMID： 25435371 DOI： 10.1038/onc.2014.379

Source DB: PubMed Journal: Oncogene ISSN： 0950-9232 Impact factor: 9.867

83 in total

1. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors: Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal: Am J Surg Pathol Date: 2012-02 Impact factor: 6.394

2. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors.

Authors: Anja Wild; Annette Ramaswamy; Peter Langer; Ilhan Celik; Volker Fendrich; Brunhilde Chaloupka; Babette Simon; Detlef K Bartsch
Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958

3. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors: Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544

4. CpG island methylator phenotype in colorectal cancer.

Authors: M Toyota; N Ahuja; M Ohe-Toyota; J G Herman; S B Baylin; J P Issa
Journal: Proc Natl Acad Sci U S A Date: 1999-07-20 Impact factor: 11.205

5. Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells.

Authors: Sheng-Hua Chu; Yan-Bin Ma; Dong-Fu Feng; Hong Zhang; Jian-Hua Qiu; Zhi-An Zhu
Journal: Mol Med Rep Date: 2011-10-11 Impact factor: 2.952

6. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors: Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544

7. Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

Authors: Daniela Furlan; Nora Sahnane; Mara Mazzoni; Roberta Pastorino; Ileana Carnevali; Michele Stefanoli; Andrea Ferretti; Anna Maria Chiaravalli; Stefano La Rosa; Carlo Capella
Journal: Virchows Arch Date: 2012-12-09 Impact factor: 4.064

Review 8. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors: James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal: J Clin Oncol Date: 2008-06-20 Impact factor: 44.544

9. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.

Authors: He-Yu Zhang; Kandelaria M Rumilla; Long Jin; Nobuki Nakamura; Gail A Stilling; Katharina H Ruebel; Timothy J Hobday; Charles Erlichman; Lori A Erickson; Ricardo V Lloyd
Journal: Endocrine Date: 2006-12 Impact factor: 3.633

Epigenetic changes in gastroenteropancreatic neuroendocrine tumours.

1. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

2. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors.

3. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

4. CpG island methylator phenotype in colorectal cancer.

5. Effect of 5-Aza-2'-deoxycytidine on SLC22A18 in glioma U251 cells.

6. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

7. Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum.

Review 8. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

9. Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors.

10. Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumors.

1. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.

Review 2. Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors.

Review 3. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.

Review 4. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.